BCOP Clinical Session — Emerging Therapies and Clinical Controversies in the Management of Diffuse Large B-Cell Lymphoma
Sunday, November 12, 2023 from 4:00 PM to 6:00 PM CST at Lone Star Ballroom A3
Available for 2.00 hours of CPE credit
Activity Number: 0217-9999-23-075-L01-P
Activity Type: An Application-Based Activity
In this session, up-to-date literature on DLBCL treatment will be presented by subject matter experts in this field. There will be interactive patient cases that will be used to highlight how to best integrate new therapies and considerations regarding the identified therapeutic controversies that exist in DLBCL. In-depth discussion on recent literature and clinical pearls on managing the safety and administration of newer therapies will also be provided.
This activity is approved for Board Certified Oncology Pharmacist (BCOP) recertification credit.
The BCOP Clinical Sessions are part of the professional development program for the recertification of board-certified oncology pharmacists by the Board of Pharmacy Specialties and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP). In order to earn the BCOP recertification credit, participants must attend the session, claim the continuing pharmacy education credit, and pass the associated posttest. Access to the BCOP Clinical Sessions posttests will be available on February 7, 2024, at www.accp.com/myaccount to anyone who has purchased access to the BCOP posttests. For participants who have not purchased access to the posttest, access can be purchased until 5:30 p.m. on Tuesday, November 14, at the ACCP Registration Desk. The deadline to submit posttests for these sessions will be December 17, 2024.
Faculty
 | Speaker: Donald C. Moore, III, Pharm.D., FCCP, BCPS
Title: BCOP Clinical Session — Emerging Therapies and Clinical Controversies in the Management of Diffuse Large B-Cell Lymphoma
Institution: Levine Cancer Institute, Atrium Health
City/State: Pineville, NC
|
 | Speaker: Shawn P. Griffin, Pharm.D., BCOP
Title: BCOP Clinical Session — Emerging Therapies and Clinical Controversies in the Management of Diffuse Large B-Cell Lymphoma
Institution: University of California, Irvine
City/State: Irvine, CA
|
 | Speaker: Katie S. Gatwood, Pharm.D., BCOP
Title: BCOP Clinical Session — Emerging Therapies and Clinical Controversies in the Management of Diffuse Large B-Cell Lymphoma
Institution: Vanderbilt University Medical Center
City/State: Nashville, TN
|
Learning Objectives
1. Assess clinical data evaluating the integration of new therapies into the first-line treatment of diffuse large B-cell lymphoma (DLBCL).
2. Compare central nervous system prophylaxis strategies for high-risk patients with DLBCL.
3. Identify considerations for sequencing new therapeutic modalities for relapsed/refractory DLBCL.
4. Apply recently published literature evaluating the role of chimeric antigen receptor T-cell therapies in DLBCL.
5. Recommend supportive care measures for managing unique toxicities associated with newer therapies for DLBCL.